What research findings exist regarding Cagrilintide and weight management and appetite regulation?
Targeting cagrilintide by the Calcr/Prlh neuron mechanism that regulates energy balance. Other research reports indicate mechanisms supporting weight reduction via AMY1 and AMY3 receptors.[1] ↗ [2] ↗
Currently, 3 original studies related to the theme of this page have been selected. The number of studies includes different designs, populations, or preparations, not commercial clinical efficacy ratings. This page is a usage-oriented positive data selection, not a systematic review or dosing recommendation. Historical studies, combination preparations, and special models are all separately indicated.
Comparison of study design and results
Results from different populations, species, materials, or follow-up times cannot be directly combined. The table below is a comparative summary of published data, not new experimental data.
| Literature | Study subjects and design | Observation and discovery | Scope of Explanation |
|---|---|---|---|
| 2026 · PMID 42260119 | Rat administration and cross-species brainstem atlas | Localizing the Calcr/Prlh neuron mechanism that locates cagrilintide regulating energy balance. | Mechanistic studies, not new human efficacy trials. |
| 2025 · PMID 40609154 | High-fat diet wild-type and RAMP1/3 knockout mice | Supports the mechanism of weight reduction through AMY1 and AMY3 receptors. | Mouse study; not human clinical effect. |
| 2021 · PMID 34798060 | Phase II of human randomized, double-blind dose exploration; 706 people | Weekly dosing group loses more weight on average than placebo. | 2021 clinical basic research, not a new 2026 trial. |
References
What neural mechanisms have energy balance studies revealed?
Localizing the Calcr/Prlh neuron mechanism that locates cagrilintide regulating energy balance.[1] ↗
Rat administration and cross-species brainstem atlas
Mechanistic studies, not new human efficacy trials.
View the Article Title and Full Citation＋
A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance.
Nature metabolism · Volume/Issue Year 2026
First published 2026-06-01 · PMID 42260119
DOI 10.1038/s42255-026-01539-3
What is the connection between amyloid receptors and changes in body weight?
Supports the mechanism of weight reduction through AMY1 and AMY3 receptors.[2] ↗
High-fat diet wild-type and RAMP1/3 knockout mice
Mouse study; not human clinical effect.
View the Article Title and Full Citation＋
Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3.
EBioMedicine · Volume/Issue Year 2025
First published 2025-07-03 · PMID 40609154
DOI 10.1016/j.ebiom.2025.105836
What did the Cagrilintide monotherapy weight loss study show?
Weekly dosing group loses more weight on average than placebo.[3] ↗
Phase II of human randomized, double-blind dose exploration; 706 people
2021 clinical basic research, not a new 2026 trial.
View the Article Title and Full Citation＋
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.
Lancet (London, England) · Volume, issue, year 2021
First published 2021-11-16 · PMID 34798060
DOI 10.1016/S0140-6736(21)01751-7
Common issues and corresponding evidence
What research findings exist regarding Cagrilintide and weight management and appetite regulation?＋
Targeting cagrilintide by the Calcr/Prlh neuron mechanism that regulates energy balance. Other research reports indicate mechanisms supporting weight reduction via AMY1 and AMY3 receptors.[1] ↗ [2] ↗
Can conclusions about Cagrilintide monotherapy be shared with CagriSema?＋
No. Single-drug dose exploration trials can support Cagrilintide's own weight management research; when CagriSema is used with another component, the combination effect must be evaluated in separate combination trials.[3] ↗
Cagrilintide—these conclusions apply to which study populations?＋
Drug administration in rats and cross-species brainstem mapping; High-fat diet wild-type and RAMP1/3 knockout mice; Human randomized, double-blind dose exploration phase II; 706 participants. Mechanistic studies, not newly added human efficacy trials.[1] ↗ [2] ↗ [3] ↗
Cagrilintide
Return to catalog specifications and batch file verification entry.
